No Data
J.P. Morgan Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating
Buy Rating Affirmed for Springworks Therapeutics: Strong Product Potential and Strategic Growth Outlook
Springworks Therapeutics Down Over 13%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk
SpringWorks Therapeutics To Present At J.P. Morgan Healthcare Conference; Webcast At 2:15 PM ET
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
Update: Springworks Therapeutics Reports Preliminary Q4, Full-Year 2024 Net Product Revenue
No Data
